Bone Marrow Mesenchymal Stem Cell Cardiac Transplantation After Ventricular Arrhythmia Risk Assessment And Mechanism Analysis

BackgroudsCardiovascular disease (CVD) is the leading cause of death in developed countries, of which nearly half is attributable to coronary heart disease (CHD). Globally, CHD accounted for one-sixth of all deaths with the World Health Organization estimating 7.2 million from CHD each year[1-2ï¼½ As the morbidity associated with CHD is increasing in developing countries, this situation is expected to become worse.One of the most devastating sequelae of CHD is the development of heart failure since patients with heart failure have 1-year survival rates that are comparable, if not worse, than patients suffering with cancel[3-5]Heart failure in the context of CHD is characterized patho -physiologically by loss of functioning cardiomyocytes secondary to ischaemic injury[6]. As cardiomyocytes have a very low potential for repair and regeneration, the ability of pharmacological agents to improve cardiac function is limited as these agents do not address the fundamental issue of cell loss. This has led to the search for a new approach in the treatment of patients with heart failure. Currently, there are two therapeutic strategies that overcome the problem of cell loss in heart failure. Heterotropic heart transplantation is able to resolve the problems of heart failure and relieve patients' symptoms, however, this treatment option is severely limited by donor organ availability and problems of...